Fig. 5

Promotion ofAnxa2expression by p-STAT3 at the transcription level. (A) The transcription factor binding motif to Anxa2 promoter, predicted by JASPAR. (B) The Pearson’s correlation plot between STAT3 and ANXA2 in the NAFLD cohort (n = 94). (C) Heatmap of ChIP-seq data of STAT3 binding for the upstream and downstream 3 kb regions of Transcription Start Site (TSS) in the pathological and normal states. D-E. WB for detecting the p-STAT3 expression in the liver of NASH mice (D) and LPS-treated hepatocytes (E). F. WB for detecting the effects from APTSTAT3-9R on p-STAT3 and ANXA2 expression in LPS-induced hepatocytes. G. The enrichment of differential peaks for STAT3 binding in Anxa2 in inflammatory and normal hepatocytes. H. Promoter luciferase reporter assay for exploring the effects of inhibiting p-STAT3 on the transcriptional activity of Anxa2. I. ChIP-qPCR for verifying the binding between p-STAT3 and Anxa2 promoter. Eight mice were included in each group. All cellular experiments were independently repeated three times. **: P < 0.01; ***: P < 0.001